It is made available under a CC-BY 4.0 International license.

1 Hypothalamic Gliosis is Associated With Multiple Cardiovascular Disease Risk Factors

-
- 2 Authors: Justin Lo, MS °; Susan J Melhorn, PhD °; Sarah Kee °; Kelsey LW Olerich, MD, PhD °;
3 Alyssa Huang, MD ^d; Dabin Yeum, PhD ^b; Alexa Beiser, PhD ^e; Sudha Seshadri, MD ^f; Charles C
4 Garl 3 Alyssa Huang, MD °; Dabin Yeum, PhD °; Alexa Beiser, PhD °; Sudha Seshadri, MD '; Charles De
4 Carli, MD ^g; Ellen A Schur, MD, MS ^b
-
- Alyssa Huang, MD "; Dabin Yeum, PhD "
Carli, MD ^g; Ellen A Schur, MD, MS ^b 4 Carli, MD ^s; Ellen A Schur, MD, MS ^p
5
^{C ^a School of Medicine, University of V}
- 5
6
-
- ^a School of Medicine, University of Washington, Seattle, WA

^b Department of Medicine, University of Washington, Seattle, WA

^c Department of Obstetrics & Gynecology, Division of Maternal-Fe
- ⁻ Department of Medicine, University of Washington, Seattle, WA
8 ^{- C} Department of Obstetrics & Gynecology, Division of Maternal-Fei
9 Weshingten, Seattle, WA 8 "Department of Obstetrics & Gynecology, Division of Maternal-Fetal Medicine, University of
9 Washington, Seattle, WA
9 ^d Denartment of Pedistrics, University of Washington, Seattle, WA
-
- 9 Washington, Seattle, WA
10 department of Pediatrics, University of Washington, Seattle, WA
11 deschool of Public Health, Boston University, Boston, MA
- 11 ^e School of Public Health, Boston University, Boston, MA
12 ^f Department of Neurology, University of Texas Health So
- 11 ^{e S}chool of Public Health, Boston University, Boston, MA
12 ^f Department of Neurology, University of Texas Health Sc
¹² festionia TY 12 ' Department of Neurology, University of Texas Health Science Center at San Antonio, San
13 Antonio, TX
14 ⁸ Department of Neurole ay , University of Colifornia, Davis, Davis, CA
-
- 14 ⁸ Department of Neurology, University of California, Davis, Davis, CA
15
16 **Antonio, Thertitle University Clippin and Cardiametabolis Pick**
- 15
16
- 16 Short title: Hypothalamic Gliosis and Cardiometabolic Risk
17
18 Corresponding author: Ellen A Schur
-
- 18
- 19 ellschur@uw.edu
20 UW Medicine Dial
- 20 UW Medicine Diabetes Institute, 750 Republican Street, Box 358062, Seattle, WA 98109
21 20 UW Medicine Diabetes Institute, 750 Republican Street, Box 358062, Seattle, WA 98206
21
22 MArd seunt: 8202
-
- 22 22 Word count: 8392
2392

23 Abstract

25

- 25 Bac<mark>kground</mark>
26 Hypothalamic gliosis is mechanistically linked to obesity and insulin resistance in rodent models.
-
- 27 We tested cross-sectional associations between radiologic measures of hypothalamic gliosis in
28 humans and clinically relevant cardiovascular disease risk factors, as well as prevalent coronary 28 humans and clinically relevant cardiovascular disease risk factors, as well as prevalent coronary
29 heart disease.
- 28 humans and clinically relevant cardiovascular disease risk factors, as well as prevalent coronary
29 heart disease.
-

30
31 **Methods** 31

- 32 Using brain MRI images from Framingham Heart Study participants (N=867; mean age, 55
- 33 years; 55% females), T2 signal intensities were extracted bilaterally from the region of interest
34 in the mediobasal hypothalamus (MBH) and reference regions in the amygdala (AMY) and
-
- 34 in the mediobasal hypothalamus (MBH) and reference regions in the amygdala (AMY) and
35 butamen (PUT). T2 signal ratios were created in which greater relative T2 signal intensity
- 35 putamen (PUT). T2 signal ratios were created in which greater relative T2 signal intensity
36 suggests gliosis. The primary measure compared MBH to AMY (MBH/AMY); a positive cor
- 36 suggests gliosis. The primary measure compared MBH to AMY (MBH/AMY); a positive control
37 artio (MBH/PUT) also assessed MBH whereas a negative control (PUT/AMY) did not. Outcome
- 37 atio (MBH/PUT) also assessed MBH whereas a negative control (PUT/AMY) did not. Outcomes
38 were BMI, HDL-C, LDL-C, fasting triglycerides, and the presence of hypertension (n=449),
- 38 vere BMI, HDL-C, LDL-C, fasting triglycerides, and the presence of hypertension (n=449),
39 diabetes mellitus (n=66), metabolic syndrome (n=254), or coronary heart disease (n=25). 39 diabetes mellitus (n=66), metabolic syndrome (n=254), or coronary heart disease (n=25).
40 Dietary risk factors for gliosis were assessed in a prospective analysis. Statistical testing w
- 30 Dietary risk factors for gliosis were assessed in a prospective analysis. Statistical testing was
41 performed using linear or logistic regression.
- 41 performed using linear or logistic regression.
42 41 performed using linear or logistic regression.
-

42

- 43 Results
44 Greater MBH/AMY T2 signal ratios were associated with higher BMI (β = 21.5 [95% CI, 15.4–
- 45 *27.6*]; *P<0.001*), higher fasting triglycerides ($β = 1.1$ [95% CI, 0.6–1.7]; *P<0.001*), lower HDL-C ($β = -20.8$ [95% CI, -40.0 to -1.6]; *P*=0.034), and presence of hypertension (odds ratio, 1.2 [95%
-
- 46 = -20.8 [95% CI, -40.0 to -1.6]; P=0.034), and presence of hypertension (odds ratio, 1.2 [95% 47 CI, 1.1 -1.4]; P=0.0088), and the latter two were independent of BMI. Findings for diabetes 47 CI, 1.1–1.4]; P=0.0088), and the latter two were independent of BMI. Findings for diabetes
48 mellitus were mixed and attenuated by adjusting for BMI. Metabolic syndrome was associa
-
- 48 mellitus were mixed and attenuated by adjusting for BMI. Metabolic syndrome was associated
49 with MBH/AMY T2 signal ratios (odds ratio. 1.3 [95% Cl. 1.1–1.6]: P<0.001). Model results were 49 with MBH/AMY T2 signal ratios (odds ratio, 1.3 [95% CI, 1.1–1.6]; P<0.001). Model results were
50 almost uniformly confirmed by the positive control ratios, whereas negative control ratios that
-
- 50 almost uniformly confirmed by the positive control ratios, whereas negative control ratios that
51 did not test the MBH were unrelated to any outcomes (all P≥0.05). T2 signal ratios were not 51 did not test the MBH were unrelated to any outcomes (all $P \ge 0.05$). T2 signal ratios were not 52 associated with prevalent coronary heart disease (all $P > 0.05$), but confidence intervals were
- 52 associated with prevalent coronary heart disease (all P>0.05), but confidence intervals were
53 vide. Self-reported percentages of macronutrient intake were not consistently related to fut
- 53 wide. Self-reported percentages of macronutrient intake were not consistently related to future
54 T2 signal ratios. 54 wide. Self-reported percentages of macronutrient intake were not consistently related to future
54 Weight T2 signal ratios.
-
-

55
56 **Conclusions** 55

- 57 Using a well-established study of cardiovascular disease development, we found evidence
- 58 linking hypothalamic gliosis to multiple cardiovascular disease risk factors, even independent of
59 adiposity. Our results highlight the need to consider neurologic mechanisms to understand and
- 59 adiposity. Our results highlight the need to consider neurologic mechanisms to understand and
60 improve cardiometabolic health.
- 59 adiposity. Our results highlight the need to consider neurologic mechanisms to understand and 61
60 improve cardiometric health.
62 improve cardiometric health.
-
- 62 62 Word count: 350

63 Non-standard Abbreviations and Acronyms
64
65 AgRP agouti-related peptide

65

-
- 66 AMY amygdala
67 BMI body-mas
- 67 BMI body mass index
68 CHD coronary heart di
- 68 CHD coronary heart disease
69 CNS central nervous system
- 69 CNS central nervous system
70 CVD cardiovascular disease
- 70 CVD cardiovascular disease
71 DM diabetes mellitus
- 71 DM diabetes mellitus
72 FDR false discovery rat
- 72 FDR false discovery rate
73 FFQ food frequency que
- 73 FFQ food frequency questionnaire
74 FHS Framingham Heart Study
- 74 FHS Framingham Heart Study
75 HDL-C high-density lipoprotein c
- 75 HDL-C high-density lipoprotein cholesterol
76 HTN hypertension
- 75 HTM hypertension
75 HTM hypertension
- 176 HTM hypertension
77 LDL-C low-density lip 77 LDL-C low-density lipoprotein cho
78 MBH mediobasal hypothalamus
79 MetS metabolic syndrome
-
- 79 MetS metabolic syndrome
80 MRI magnetic resonance
- 80 MRI magnetic resonance imaging
81 POMC pro-opiomelanocortin
- 81 POMC pro-opiomelanocortin
82 PUT putamen
- es a compresentance com-
82 PUT putamen
- es a parament
83 PVN paraventr 83 PVN paraventricular nu
84 ROI region of interest
85 SNA sympathetic nerve
-
- 85 SNA sympathetic nerve activity
86 T1D type 1 diabetes
- 86 T1D type 1 diabetes
87 T2D type 2 diabetes
- type 2 diabetes 87 T2D type 2 diabetes

It is made available under a CC-BY 4.0 International license.

88 Introduction

89 Obesity, hypertension (HTN), metabolic syndrome (MetS), and type 2 diabetes (T2D) are well-
90 established risk factors for increased cardiovascular disease (CVD) morbidity and mortality. 91 However, central nervous system (CNS) involvement in the pathogenesis of CVD risk factors, 91 However, central nervous system (CNS) involvement in the pathogenesis of CVD risk factors, 92 — including obesity and T2D, is increasingly recognized.* A robust preclinical literature
02 A demonstrates that dist indused abosity in animal models is saysally related to sally! 93 demonstrates that diet-induced obesity in animal models is causally related to cellular 94 — inflammatory responses in the hypothalamus." Furthermore, T2D is linked to the remodeling of
05 — avtreselly lar motrix structures that seeffeld neurons and their groantis sennestions 3 la extracellular matrix structures that scaffold neurons and their synaptic connections.³ In
96 In humans, ex vivo histopathological and *in vivo* neuroimaging studies support that cellular and 97 tissue-level alterations consistent with hypothalamic gliosis are present in the human 97 tissue-level alterations consistent with hypothalamic gliosis are present in the human 98 hypothalamus in association with obesity and metabolic disease.⁴ Prospective studies further
08 Prospect a relative shorify and T3D pathograpeis by chausing that the extent of clineis, defined a 99 support a role in obesity and T2D pathogenesis by showing that the extent of gliosis, defined as
100 proliferation and inflammatory activation of glia, is associated with weight gain and progressive 100 proliferation and inflammatory activation of glia, is associated with weight gain and progressive insulin resistance in children and adults with overweight or obesity.4,5 101 Moreover, arcuate 102 nucleus inflammation may mean be increased atherogenic risk associated with
102 nucleus conceliers in real on ⁶ Further studies have linked by a thelesse inflammation to hypogonadism in males. $^{\circ}$ Further studies have linked hypothalamic inflammation to MetS, T2D,
104 Fund imperied clusese telegance 5,7,8 Therefore, bunethalamic inflammation and cliseis sould. and impaired glucose tolerance.^{5,7,8} Therefore, hypothalamic inflammation and gliosis could
105 Indirectly increase the risk of CVD by promoting metabolic dysregulation, chronic systemic 106 inflammation, and/or atherogenic lipid profiles.

107 http://elicamatively. diet-induced hypothalamic inflammation in the MBH and its arcuate 108 hucleus could directly contribute to CVD development. The arcuate nucleus receives sensory 109 inputs and transmits intra- and extra-hypothalamic communications to govern homeostatic $10₉$ inputs and transmits and extra-hypothalamic communications to govern homeostatic

It is made available under a CC-BY 4.0 International license.

127 reference approved projects. JL had full access to the data and is responsible for the integrity.
127 references 127 of the data analysis in the study.
128 Study population

129 In this cross-sectional study, 905 MRI images were provided from magnetic resonance imaging 130 (MRI) exams conducted on the FHS Offspring and Generation 3 cohorts (Figure S1). The FHS is a 130 (MRI) exams conducted on the FHS Offspring and Generation 3 cohorts (Figure S1). The FHS is a 131 longitudinal, multigenerational observational cohort study investigating cardiovascular risk
...

It is made available under a CC-BY 4.0 International license.

147 Outcomes of interest
148 Outcomes of interest in this study were cardiovascular risk factors including body mass index 149 (BMI), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), 150 fasting triglycerides, HTN, diabetes mellitus (DM), and MetS, as well as prevalent coronary heart 151 disease (CHD). BMI was calculated from height and weight measurements. HDL-C, LDL-C, and 152 fasting (at least 8 hours prior to blood sample collection) triglycerides were measured in 153 ethylenediaminetetraacetic acid serum tests. The presence of HTN was based on the American

 153 ethylenediaminetetraacetic acid serum tests. The presence of HTM was based on the American on the American

It is made available under a CC-BY 4.0 International license.

154 Heart Association stage 1 and stage 2 HTN definitions as either systolic blood pressure greater
155 than or equal to 130 mmHg, diastolic blood pressure greater than or equal to 80 mmHg, and/or 155 than or equal to 130 mmHg, diastolic blood pressure greater than or equal to 80 mmHg, and or e
156 the president treatment for UTN ¹⁴ DM were defined as a their faction blood always are starting an 156 — receiving treatment for HTN.¹⁴ DM was defined as either fasting blood glucose greater than or
157 — equal to 126 mg/dl usadem blood glucose greater than or equal to 200 mg/dl .and/eq 157 equal to 126 mg/dL, random blood glucose greater than or equal to 200 mg/dL, and/or
158 treatment for DM. Distinction between type 1 diabetes (T1D) and T2D was not ascertained but 158 treatment for DM. Distinction between type 1 diabetes (T1D) and T2D was not as not as not as not as not as 159 – most cases were assumed to be T2D, as discussed in previous literature.¹⁵ MetS was defined as
159 – having 2.0 mars, exiteria af matabalis abnarmalities according to the American Haert. 160 . According and the National Heart Lune and Place Institute definition¹⁶. A matelia b 161 Association and the National Heart, Lung, and Blood Institute definition¹⁶: 1) systolic blood
163 : Insecure areater than ar cauel to 130 mmlla, diastelie blood recesses areater than ar caue 162 pressure greater than or equal to 130 mmHg, diastolic blood pressure greater than or equal to
163 S5 mmHg, or receiving treatment for HTN; 2) fasting blood glucose greater than or equal to 100 164 mg/dL or receiving treatment for elevated blood glucose; 3) HDL-C less than 40 mg/dL in males 165 or 50 mg/dL in females or receiving treatment for low HDL-C; 4) triglycerides greater than or 166 equal to 150 mg/dL or receiving treatment for high triglycerides; 5) waist circumference greater 167 than or equal to 102 cm for males or 88 cm for females. Finally, CHD was defined as 168 manifestations of CHD before or during the FHS study period, including myocardial infarction, 169 coronary insufficiency, angina pectoris, sudden death from CHD, and non-sudden death from 169 coronary insufficiency, angina pectoris, sudden death from CHD, and non-sudden death from CHD, 170 CHD, and was adjudicated by FHS investigators.

171 Dietary Exposures
172 – In a prospective cohort analysis, the relation of dietary exposures to subsequent MRI findings 173 was tested. Dietary exposures were collected from a Food Frequency Questionnaire (FFQ) 174 administered at the FHS exam prior to MRI acquisition (Offspring cohort, examination 8; 175 Generation 3 cohort, examination 2). Daily consumptions of the proportions of total fat, total 175 Generation 3 cohort, examination 2). Daily consumptions of the proportions of the

It is made available under a CC-BY 4.0 International license.

176 carbohydrates, total protein, total sugar, fructose, sucrose, and saturated fat of total energy
177 intake were calculated by dividing each dietary exposure intake (kilocalories consumed) by the 178 average daily caloric intake. 51 participants were missing FFQ data and 2 participants with 179 implausible values for the proportions of total fat and saturated fat were removed from all 180 dietary analyses, leaving a total sample of N=814. There was a greater percentage of females in 181 the group of participants with FFQ data compared to those without; otherwise, the two groups 182 did not differ in other relevant characteristics such as age, smoking status, and BMI (data not 182 did not differ in other relevant characteristics such as age, smoking status, and BMI (data not
183 dibiwih 183 shown).
184 Covariates

185 Age, sex, and smoking status were collected and reported in the FHS exam data. Information on

186 an individual's treatment status for HTN, DM, and lipid levels was determined from both self-

187 reported exam data and medication review. Physical activity was captured based on a physical

188 activity index derived from self-reported levels of activity during a typical 24-hour period.

188 activity index derived from self-reported levels of activity during a typical 24-hour period.
199 a Mathodo to construct the inhusing astivity index are described in detail electricity 17 Methods to construct the physical activity index are described in detail elsewhere.17 ¹⁸⁹

190 MRI Acquisition and Analysis
191 High-resolution T2-weighted axial brain images were analyzed in Horos Medical Image Software 192 by two independent raters (Figure 1). The image slice superior to the optic chiasm, with visible 193 optic tracts and mammillary bodies, was identified as the MBH slice of interest. The MBH ROI 194 was placed bilaterally in the anterior hypothalamic area adjacent to the 3rd ventricle to 195 encompass the region of the arcuate nucleus. Slices inferior and superior were selected based 196 on clear anatomical landmarks for the control ROIs (i.e., AMY and PUT). T2 signal intensities 197 were extracted bilaterally from the regions (i.e., MBH, AMY, and PUT). The signal intensities 198 were then used to create ratios for the left, right, and bilateral mean for our primary measure

 198 were then used to create ratio \sim the left, right, and bilateral mean for our primary measure \sim

It is made available under a CC-BY 4.0 International license.

206 Statistical analysis

207 Multiple linear regression was used to analyze continuous outcomes (i.e., BMI, LDL-C, HDL-C, 208 and triglycerides); multiple logistic regression was used to analyze binary outcomes (i.e., HTN, 209 DM, MetS, and CHD). Coefficients and confidence intervals are reported as the estimated 210 change in outcome per 1 unit difference in the predictor variable, while odds ratios and 211 confidence intervals are reported as the estimated change in odds per 1 SD difference in the 212 predictor variable. Fasting triglyceride levels were right-skewed and natural logarithm-213 transformed for analysis. T2 signal ratios for the primary exposure, positive control, and 214 negative control predictors were natural logarithm transformed and used as predictors in the 215 models to satisfy conditions of normality. Age and sex were included as covariates in the base 216 model (Model 1). Current smoking status was added in subsequent models (Model 2), while risk 217 factor treatment status was further adjusted for outcomes except MetS (Model 3). BMI was 218 added in fully adjusted models when appropriate. Table S1 describes the full set of covariates 219 included in the models. We evaluated statistical significance using two-sided tests at the $P<0.05$ 219 included in the models. We evaluated statistical significance using two-sided tests at the P<0.05 220 level, uncorrected for multiple comparisons for our a priori outcomes, to test associations with

It is made available under a CC-BY 4.0 International license.

221 and without adjustment for confounders such as BMI. Statistics were computed in R version

234 age and was 55% female. The mean BMI was in the overweight range, whereas 34.6% of the
235 sample had a BMI in the obesity range. Current smoking (5.4%), diabetes treatment (5.4%), and 235 sample had a BMI in the obesity range. Current smoking (5.4%), diabetes treatment (5.4%), and

236 prevalent CHD (2.9%) were rare.
237 Body mass index (BMI)

238 MBH/AMY T2 signal ratios and BMI were positively associated (Figure 2A). The positive

239 association between MBH/AMY T2 signal ratios and BMI persisted after adjusting for age, sex,

240 smoking status, and diabetes treatment (Table 2). Coefficients estimate that a 0.1 unit increase

241 in the natural logarithm-transformed MBH/AMY T2 signal ratio would be associated with a 2.2

 242 in the natural logarithm-transformed MBH/Thransformed MADH/DHT) T2 signal ratio would be associated with a 2.2 242 kg/m² (95% Cl 1.5–2.8) higher BMI. The positive control (MBH/PUT) T2 signal ratio was also

It is made available under a CC-BY 4.0 International license.

- 243 positively associated with BMI in all models, whereas there were null associations for the
244 negative control (PUT/AMY) T2 signal ratio and BMI (Table 2).
-
- 244 negative control (PUT/AMY) T2 signal ratio and BMI (Table 2).
- 245 HDL cholesterol (HDL-C)
246 There was a negative association between MBH/AMY T2 signal ratios and HDL-C (Figure 2B).
- 247 Negative associations were present at all levels of adjustment in models testing the primary
- 248 exposure (MBH/AMY T2 signal ratio) and the positive control (MBH/PUT) T2 signal ratio (Table
- 249 exposined 2), including after adjustment for BMI. PUT/AMY T2 signal ratios were not associated with HDL-249 2), including after adjustment for BMI. PUT/AMY T2 signal ratios were not associated with HDL-
- 250 C concentrations (Table 2).
251 LDL cholesterol (LDL-C)
-
- 252 The primary exposure T2 signal ratios were not associated with LDL-C in model 1 (Figure 2C) nor
- 253 The primary further adjusted models (Table 2). The positive and negative control T2 signal ratios were 253 any further adjusted models (Table 2). The positive and negative control T2 signal ratios were
- 254 similarly not associated with LDL-C (Table 2).

- 255 Triglycerides
256 There were positive associations between the MBH/AMY T2 signal ratios and fasting
- 257 triglycerides in Model 1 (Figure 2D), as well as Models 2 and 3 (Table 2). However, the
- 258 magnitude of the association was reduced such that only a trend persisted after further
- 259 adjusting for BMI in the fully adjusted model (Table 2, $P=0.076$). In contrast, MBH/PUTT2 signal
- 260 ratios were uniformly positively associated with natural logarithm-transformed fasting
- 261 trigly cerides, including after adjustment for BMI. PUT/AMY T2 signal ratios were not
- 262 significantly associated with fasting triglycerides (Table 2). $\frac{1}{2}$ significantly associated with fasting trigly certain (Table 2).

It is made available under a CC-BY 4.0 International license.

- 263 Hypertension
264 For all models, there were positive associations between MBH/AMY T2 signal ratios and the
- 265 presence of HTN (Figure 3). Model 1 estimates that a 1SD difference in the natural-logarithm
- 266 transformed MBH/AMY T2 signal ratio is associated with a 1.4 (95% CI 1.2-1.6) times greater
- 267 odds of HTN diagnosis. Positive control T2 signal ratios were also positively associated with the
- 268 presence of HTN, except for in the fully adjusted model ($P=0.12$). No associations were found 268 presence of HTN, except for in the fully adjusted model (P=0.12). No associations were found
- 269 with the negative control T2 signal ratio (Figure 3).
-
- 270 Diabetes mellitus (DM)
271 MBH/AMY T2 signal ratios were not associated with prevalent DM in any models (Figure 3).
- 272 MBH/PUT T2 signal ratios were associated with higher odds of prevalent DM (Figure 3), but not
- 272 MBH/PUT T2 signal ratios were associated with higher odds of prevalent DM (Figure 3), but not 273 in the fully adjusted model that included BMI (P=0.21). PUT/AMY T2 signal ratios were not
- 274 associated with DM (Figure 3).
275 Metabolic syndrome (MetS)
-
- 276 MBH/AMY T2 signal ratios were positively associated with prevalent MetS in all models (Figure
- 277 3), including after adjustment for age, sex, smoking status, and physical activity. The MBH/PUT
- 278 T2 signal ratios were also positively associated with prevalent MetS at all levels of adjustment,
- 279 whereas the PUT/AMY T2 signal ratios were not associated (Figure 3). 279 whereas the PUT/AMY T2 signal ratios were not associated (Figure 3).
-
- 280 Coronary heart disease (CHD)
281 Among 25 individuals with prevalent CHD, 20 individuals were diagnosed with CHD prior to
- 282 their MRI exam. There were no associations between the MBH/AMY T2 signal ratios and
- 283 prevalent CHD (Figure 3), and all models returned coefficients with wide confidence intervals. 283 prevalent CHD (Figure 3), and all models returned coefficients with wide confidence intervals.

It is made available under a CC-BY 4.0 International license.

284 Neither positive nor negative control T2 signal ratios were associated with prevalent CHD

285 (Figure 3).
286 Sensitivity analyses

287 The timing of health information collection and MRI assessment across the sample varied by 288 individual and cohort. Results adjusted for time intervals between FHS health examination and

289 MRI examination are presented in Tables S3 and S4, and findings were unchanged from the 289 MRI examination are presented in Tables S3 and S4, and findings were unchanged from the

290 primary analysis.
291 Dietary exposures in relation to MBH gliosis

292 In analyses adjusting for age, sex, and time interval between dietary exposures and MRI, no 293 statistically significant prospective associations (Table S5) were found between self-reported 294 intake of total fat (β =0.04 [95% CI, -0.02 to 0.11]; P=0.19), total carbohydrates (β =-0.04 [95% 295 CI, –0.09 to 0.01]; P=0.15), total protein (β = 0.09 [95% CI, –0.04 to 0.22]; P=0.19), fructose (β = 296 -0.03 [95% CI, -0.22 to 0.17]; P=0.78), sucrose (β = -0.08 [95% CI, -0.20 to 0.04]; P=0.19), or 297 saturated fat $(\beta = 0.12$ [95% CI, -0.04 to 0.29]; P=0.14) and the degree of MBH gliosis (natural 298 logarithm transformed MBH/AMY T2 signal ratio) assessed at MRI examinations conducted, on 299 average, 7 years after completion of FFQs. Negative associations were found between the 300 proportion of daily total carbohydrate intake ($\beta = -0.08$ [95% CI, -0.16 to 0.00]; P=0.04) and 301 sucrose intake (β =–0.20 [95% CI, –0.38 to –0.02]; P=0.03) and the positive control (MBH/PUT) 302 T2 signal ratio. These associations did not meet the FDR correction criteria at q<0.05. No 303 associations were found between dietary exposures and the negative control (PUT/AMY) T2 304 signal ratios (Table S5). Exploratory analyses demonstrated a significant interaction between 305 the BMI group and the proportion of daily saturated fat intake on the degree of MBH gliosis 305 the BMI group and the proportion of daily saturated fat intake on the degree of MBH gliosis

It is made available under a CC-BY 4.0 International license.

306 (natural logarithm transformed MBH/AMY T2 signal ratio) after covariate adjustment (β-
307 int=0.25 [95% Cl, 0.04–0.46]; P-int=0.02). As shown in Figure S2, stratified analyses revealed

- 307 int=0.25 [95% CI, 0.04–0.46]; P-int=0.02). As shown in Figure S2, stratified analyses revealed opposing directions of slopes by BMI group (BMI<25 kg/m2 308 : β=–0.31 [95% CI, –0.60 to –0.15];
- 309 P=0.04; 25 kg/m^≤BMI<30 kg/m^: β=0.16 [95% CI, −0.08 to 0.40]; P=0.20; BMI ≥30 kg/m^:
319 8 9 33 [950′ CI 9 98 ts 9 53]; B 9 34).
- 310 p=0.22 [95% CI, –0.08 to 0.53]; P=0.14).

311 Discussion

312 Using a well-established study of CVD development, we found evidence linking hypothalamic
313 Paliosis to multiple CVD risk factors. Prior human studies indicate that obesity and metabolic 314 dysregulation, including glucose intolerance and T2D, are associated with histologic and 314 dysregulation, including glucose intolerance and T2D, are associated with histologic and 315 radiologic signs of MBH inflammation and gliosis.⁴ In the largest sample studied to date, we
245 found stress reseitive secondations of MBH aliseit with PML and MatG sure artice resultance $317 - f$ indings 7^{18} Novel recults linked MBH gliosis to low UDL. C and increased previous of UTN 317 hindings.^{7,18} Novel results linked MBH gliosis to low HDL-C and increased prevalence of HTN.
218 These secondations nominal with adjustment for PML currenting that it is not solal ush saitu 318 These associations persisted with adjustment for BMI, suggesting that it is not solely obesity-
319 Frelated metabolic dysfunction driving the result, but that the function of central pathways 320 regulating circulating lipids and blood pressure could be directly impacted by glial cell 321 inflammatory responses in the MBH. Although we did not find associations between 322 hypothalamic gliosis and a clinical diagnosis of CHD, the sample size was small, and incident 323 disease was not assessed. In sum, these findings add to an expanding body of evidence 324 demonstrating the influence of CNS factors, namely hypothalamic inflammation and gliosis, on 325 the pathogenesis of cardiometabolic risk and, potentially, CVD itself. 326 **the pathogenesis of cardiometabolic risk and pathogenesis of LDL-C and triglycerides confer an** 326 Low levels of circulating HDL-C and high levels of LDL-C and triglycerides confer an 327 increased risk for CVD development and are strongly associated with obesity.^{19,20} However, few

It is made available under a CC-BY 4.0 International license.

328 studies have closely examined the relationship of dyslipidemia to diet-induced hypothalamic
329 inflammation. A study of 41 healthy adult males found that longer MBH T2 relaxation times 329 inflammation. A study of 41 healthy adult males found that longer MBH T2 relaxation times 330 were associated with higher LDL-C levels but not associated with HDL-C or triglyceride levels." In 330 In
221 In a stace costional study. Kroutzer at al. found no accociation between unilateral left cided. 331 a cross-sectional study, Kreutzer et al. found no association between unilateral left-sided MBH/AMY T2 signal ratios and triglyceride levels among 111 adults with and without obesity.²¹
223 Contremute these smaller studies, we absented a strang negative association between MPH. 333 Contrary to these smaller studies, we observed a strong negative association between MBH
334 Spliosis and HDL-C. The negative association was present even after adjusting for BMI, a finding 335 that is consistent with the hypothesis that the severity of hypothalamic inflammation is directly 336 related to the worsening of obesity-associated metabolic dysregulation of both peripheral 337 glucose and blood lipids. Apolipoprotein A-I deficiency in mice produces a phenotype that 338 recapitulates many features of MetS including increased adiposity, visceral and hepatic fat 339 deposition, hypertriglyceridemia, glucose intolerance, and low HDL-C and is accompanied by 339 deposition, hypertriglyceridemia, glucose intolerance, and low HDL-C and is accompanied by 340 Inflammation and reactive astrocytosis in the MBH.²² Intriguingly, administering reconstituted
244 Internace UNI Groups lised values of astrogute inflammatory markers, indicating a natentially 341 human HDL-C normalized values of astrocyte inflammatory markers, indicating a potentially
342 protective role for HDL-C in reducing hypothalamic inflammation with concomitant 342 protective role for HD-C in reducing hypothalamic inflammation with concentration. improvement in some features of MetS.²² On the contrary, randomized trials of
244 Only website the ranies to increase UDL Glovels have not been shown to designed. 345 pharmacotherapies to increase HDL-C levels have no been shown to determine $\frac{23-25}{2}$ Monothelese circum the streng relationships between level IDL-C and altered 345 humans.^{23–25} Nonetheless, given the strong relationships between low HDL-C and altered
245 hunathalamia tiasua structure in the aument study, hunathalamia aliasis renormates navy 346 hypothalamic tissue structure in the current study, hypothalamic gliosis represents a novel,
347 Sargely unexplored mechanism to advance understanding of both the etiology of low HDL-C in 348 obesity and contradictory findings regarding the benefits of raising HDL-C for reducing CVD risk. 349 We also found evidence of a positive association between MBH/AMY T2 signal ratios and 349.99 We also found evidence of a positive association between MBH/AMY T2 signal ratio and

It is made available under a CC-BY 4.0 International license.

350 fasting triglyceride concentrations. The association was attenuated when adjusting for BMI,
351 indicating that high levels of peripheral adiposity at least partially explain the relationship.

352 Lastly, we did not observe associations between T2 signal ratios and LDL-C. Nevertheless, the

353 MBH's role in energy homeostasis and the current findings should prompt further investigation

354 into dysregulation of circulating lipids by hypothalamic inflammation.

355 Preclinical evidence points to the role of the arcuate nucleus in altering blood pressure 356 bethrough SNA.^{10,26} High-fat diets and obesity activate the arcuate nucleus, located within the 356 through SNA.^{10,26} High-fat diets and obesity activate the arcuate nucleus, located within the
257 - MPU to elter SNA rejeccily through insulin and leatin signaling ^{10,26} Reth hormones hind to 357 Both HDH, to alter SNA primarily through insulin and leptin signaling.^{10,26} Both hormones bind to 357
258 - Jone Aniamalanaeartin (DOMC) and a sauti related nantide (AnDD) neurone in the argusta 358 pro-opiomelanocortin (POMC) and agouti-related peptide (AgRP) neurons in the arcuate
359 nucleus, which in turn relay signals to other hypothalamic sites, such as the paraventricular 359 nucleus, which in turn relay signals to other hypothalamic sites, such as the paraventricular 360 nucleus (PVN), an important regulator of SNA and blood pressure.^{27,28} Specifically, POMC
201 - Deurens release a melaneaute stimulating bermane that estivates deuratream melanea 361 neurons release α –melanocyte-stimulating hormone that activates downstream melanocortin-4
362 neceptors to increase SNA in the PVN, while AgRP neurons release neuropeptide Y (NPY) that 362 receptors to increase station and PVN, mille Agrip neurons release neuropeptide Y (NPY) that suppresses sympathoinhibitory effects in the PVN.^{29–33} Our results provide novel evidence that
264 O MPU sliggie a diet indused phanomenon is accesiated with UTN in humane. While the event 364 MBH gliosis, a diet-induced phenomenon, is associated with HTN in humans. While the exact
365 mechanisms remain uncertain, hyperleptinemia, hyperinsulinemia, and/or local inflammation 366 itself may exacerbate arcuate nucleus-induced SNA, thereby raising blood pressure via the well-367 defined neural circuitry outlined above. In the current study, associations were attenuated but 368 still present after adjusting for BMI, providing further rationale for investigating how 369 inflammation and gliosis in the arcuate nucleus region could evoke adiposity-independent 370 effects on neural circuits controlling blood pressure. 370 effects on neural circuits controlling blood pressure.

It is made available under a CC-BY 4.0 International license.

388 authors, may have resulted from an inflammatory response by glial cells increasing water 388 authors, may have resulted from an inflammatory response by glial cells increasing water. 389 Auptake, potentially damaging local microenvironments.' Results from the present study are
200 Aeneistent with Kullman et al. Such erece sectional findings provide avidence that MetS and 390 consistent with Kullman et al. Such cross-sectional findings provide evidence that MetS and its
391 clinical components are related to hypothalamic inflammation, and potentially, structural

387 hypothalamus, thalamus, and fornix. Water content in these regions, as suggested by the

392 changes specific to the hypothalamus. Whether the severity of metabolic dysregulation (e.g., $\frac{3}{3}$ changes specific to the hypothalamus. Whenher the severity of metabolic dysregulation (e.g.,

It is made available under a CC-BY 4.0 International license.

393 higher blood pressure, worse insulin resistance) or the presence of a greater number of CVD
394 bisk factors is related to the degree of inflammation and structural damage presents a focus for 394 risk factors is related to the degree of inflammation and structural damage presents a focus for

395 future investigations. Hypothalamic gliosis is diet-induced in preclinical models.³⁴ We were unable to identify 396 Wester Hypothalamic gliosis is diet-induced in preclinical models.³⁴ We were unable to identify
207 Wester this precisent dis 397 consistent dietary predictors of MBH T2 signal ratios in humans in this prospective analysis.
398 However, the prospective association between lower daily proportion of total carbohydrate 399 consumption and greater evidence of gliosis, as assessed by the positive control T2 signal ratio. 400 suggests that the proportions of macronutrients in daily diet might be influential. Prior findings 401 suggests that the proportions of macronutrients in daily diet might be influential. Prior findings $\frac{35}{2}$ and because $\frac{21}{4}$ studies bightight seturated fot consumption as a massible wisk factor 101 in preclinical35 and human²¹ studies highlight saturated fat consumption as a possible risk factor
102 of far MPH clienia in humana. Given the inverse relationship hatureen sarkehudrate and fat. 402 for MBH gliosis in humans. Given the inverse relationship between carbohydrate and fat
403 consumption, the current findings of greater evidence of gliosis with lower carbohydrate intake 404 could be seen as supportive of the role of dietary fats in instigating hypothalamic inflammation. 405 Furthermore, the effect of saturated fat consumption on the degree of MBH gliosis was 406 Furthermore, the effect of satus in the effect of the effect in plies that those with overweight or obesity may have a 407 different susceptibility to gliosis related to saturated fat consumption than individuals 408 maintaining weight in the normal range. Further research capable of discerning risk and 409 protective factors for hypothalamic gliosis (e.g., genetics) in relation to precisely measured 409 protective factors for hypothalamic gliosis (e.g., genetics) in relation to precisely measured 410 dietary exposures is needed.
411 There are several strengths to this study. This is the largest study to date providing

412 evidence of associations between hypothalamic gliosis and multiple CVD risk factors, including 413 evidence of an absolutions of a social data in the social mode is an absociate the multiple righ-414 guality data measured and collected by FHS investigators. Limitations to this study include the

 $\frac{1}{4}$ and $\frac{1}{4}$ and collected by FHS investigations. Limitations to this study include the study include the study in

It is made available under a CC-BY 4.0 International license.

415 lack of statistical power to detect associations with CHD itself in a relatively young and healthy
416 study population with few CHD cases. Additionally, participants with longstanding CHD or DM 417 may have adapted lifestyle modification (e.g., diet changes or weight loss) with the potential to 418 affect hypothalamic gliosis. Furthermore, most subjects self-identified as White, limiting the 419 interpretation of our results to a select population, and we were not powered to determine 420 sex-specific associations. MRI images are an indirect measure of MBH gliosis; higher T2 signal 421 intensity can be due to local edema, tumors, or autoimmune inflammation, but in community-422 based participants in an observational study, these pathologies are unlikely. Imaging variability 423 from factors such as BO inhomogeneity may have limited our ability to detect smaller effect 424 sizes. Lastly, misclassification of dietary exposures could arise due to self-report methodology 425 and any changes in habitual intake that occurred during the several-year interim before MRI 425 and any changes in habitual intake that occurred during the several-year interim before MRI 426 images were captured.

 428 In sum, the current study focuses attention on the CNS and on the evolving 428 Understanding of how weight gain might relate to increased CVD risk.^{36,37} Weight gain and/or
428 Weight factors may numerate hunathalamia inflammation which acts as a shared risk factor far 429 dietary factors may promote hypothalamic inflammation which acts as a shared risk factor for
430 obesity and CVD that fails to fully resolve with lifestyle changes alone. While behavioral 434 observations that fails to fully resolve that in Experimental changes alone. CVD risk 38 CLD 4 cm 431 Ainterventions that improve metabolic status do not always reduce CVD risk,³⁸ GLP-1 agonists
433 Abot nuomete substantial weight less as well as baristric surgery de benefit sardiovassular. 432 that promote substantial weight loss as well as barriatric surgery do benefit cardiovascular $\frac{1}{2}$ 433 Phealth.^{39–44} Preclinical and human studies show improvement in hypothalamic inflammation
424 Putth limetutida⁴² and bariatric surram ^{8,43}respectively. with liraglutide⁴² and bariatric surgery,^{8,43} respectively.
435 These robust cross-sectional findings support investigations to clarify the role of

436 hypothalamic gliosis in CVD pathogenesis. Future epidemiologic and clinical studies could $\frac{4}{3}$ 6 heralamic gliosis in CVD pathogenesis. Future epidemiologic and clinical studies could

It is made available under a CC-BY 4.0 International license.

It is made available under a CC-BY 4.0 International license.

459

460 Disclosures

461 EAS has provided consultation to Amgen, Inc. The other authors report no conflicts.

462

- 463 Supplemental Material
- 464 Figure S1-S2
- 465 Table S1–S5

It is made available under a CC-BY 4.0 International license.

466 References

- 1. Sewaybricker Le, Huang A, Chandrasekaran S, Melhorn S, Schur Ea. The Significance of
468 Hypothalamic Inflammation and Gliosis for the Pathogenesis of Obesity in Humans. End 468 **Hypothalamic Inflammation and Gliosis for the Pathogenesis of Obesity in Humans.** *Endocr***
469** *Rev. 2022;44:281–296.* Rev. 2022;44:281–296.
170 2. García-Cáceres C. Balland E. Prevot V. Luquet S. Woods SC. Koch M. Horvath TL. Yi C-X.
- 471 Chowen JA, Verkhratsky A, et al. Role of astrocytes, microglia, and tanycytes in brain
472 control of systemic metabolism. Nat Neurosci. 2019;22:7–14. control of systemic metabolism. Nat Neurosci. 2019;22:7-14.
- 473 3. Alonge KM, Mirzadeh Z, Scarlett JM, Logsdon AF, Brown JM, Cabrales E, Chan CK, Kaiyala 474 KJ, Bentsen MA, Banks WA, et al. Hypothalamic perineuronal net assembly is required for
475 sustained diabetes remission induced by fibroblast growth factor 1 in rats. Nat Metab. 475 Sustained diabetes remission induced by fibroblast growth factor 1 in rats. Nat Metab.
476 3000.3:400F 4033 475 sustained diabetes remission induced by fibroblast growth factor 1 in rats. Nat Metab.
- 476 2020;2:1025–1033. 478 degree State Party and the Legisland State of the State radio location of the Spring Burn Spring (Silver Spring).
479 degree 2001-201770-1770 478 gliosis predicts adiposity gain in children at risk for obesity. Obesity (Silver Spring).
479 2021;29:1770–1779. 479 2021;29:1770–1779.
- 481 Utzschneider KM, Schur EA. Evidence That Hypothalamic Gliosis Is Related to Impaired
482 Glucose Homeostasis in Adults With Obesity. Diabetes Care. 2021;45:416–424. Glucose Homeostasis in Adults With Obesity. Diabetes Care. 2021;45:416-424.
- 483 G. Dorfman MD, Monfeuga T, Melhorn SJ, Kanter JE, Frey JM, Fasnacht RD, Chandran A, Lala 484 6. L, Velasco I, Rubinow KB, et al. Central androgen action reverses hypothalamic astrogliosis
485 and atherogenic risk factors induced by orchiectomy and high-fat diet feeding in male 485 and atherogenic risk factors induced by orchiectomy and high-fat diet feeding in male
486 mice. Am J Physiol Endocrinol Metab. 2023;324:E461–E475. mice. Am J Physiol Endocrinol Metab. 2023;324:E461-E475.
- 487 7. Kullmann S, Abbas Z, Machann J, Shah NJ, Scheffler K, Birkenfeld AL, Häring H-U, Fritsche 488 A, Heni M, Preissl H. Investigating obesity-associated brain inflammation using
489 auantitative water content mapping. Journal of Neuroendocrinoloav. 2020:32: quantitative water content mapping. Journal of Neuroendocrinology. 2020;32:e12907.
- 490 8. van de Sande-Lee S, Melhorn SJ, Rachid B, Rodovalho S, De-Lima-Junior JC, Campos BM, 491 Pedro T, Beltramini GC, Chaim EA, Pareja JC, et al. Radiologic evidence that hypothalamic
492 gliosis is improved after bariatric surgery in obese women with type 2 diabetes. Int J Obes 492 Pedro T, Beltramini GC, Beltramini E., Pareja JC, Pedro That Progressive That hypothalamics
492 Pedro T, Chaim Ea, Pareja JC, et al. Radiologic evidence that hypothalamics of the displace that hypothala
493 Pedro T, 20 492 gliosis is improved after bariatric surgery in obese women with type 2 diabetes. *Int J Obes*
493 (Lond). 2020;44:178–185. (*Lond*). 2020;44:178–185.
494 9. Jais A, Brüning JC. Arcuate Nucleus-Dependent Regulation of Metabolism—Pathways to
- 495 Obesity and Diabetes Mellitus. Endocr Rev. 2021;43:314-328.
- 496 10. Guyenet PG, Stornetta RL, Souza GMPR, Abbott SBG, Brooks VL. Neuronal Networks in 10. Guyenet Page 10. Guyenet Page State State State Corp. 2020; 76:300–311.
497 Hypertension: Recent Advances. Hypertension. 2020; 76:300–311. 497 Hypertension: Recent Advances. Hypertension. 2020;76:300–311.

It is made available under a CC-BY 4.0 International license.

- 1988 11. Annual WB, Feinleib M, McNamara PM, Garrison M, Garrison Promince Mgarrison
499 1970-110-281-299
588 1970-110-281-299 499 coronary heart disease in families. The Framingham offspring study. Am J Epidemiol.
500 1979;110:281–290.
- 500 1979;110:281–290.
501 12. Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA, Benjamin EJ, D'Agostino RB, Fox CS, 502 Larson MG, Murabito JM, et al. The Third Generation Cohort of the National Heart, Lung,
503 and Blood Institute's Framingham Heart Study: design, recruitment, and initial 503 and Blood Institute's Framingham Heart Study: design, recruitment, and initial
504 examination. Am J Epidemiol. 2007;165:1328–1335. examination. Am J Epidemiol. 2007; 165: 1328-1335.
- 505 13. Massaro JM, D'Agostino RB, Sullivan LM, Beiser A, DeCarli C, Au R, Elias MF, Wolf PA. 506 13. Managing and analysing data from a large-scale study on Framingham Offspring relating
507 http://www.brain structure to cognitive function. Stat Med. 2004;23:351-367. brain structure to cognitive function. Stat Med. 2004;23:351-367.
- 508 14. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C,
- 509 14. DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2017
510 1ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PC
- 510 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the
511 Prevention, Detection, Evaluation, and Management of High Blood Pressure in Ac
- 511 Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A
512 **Shaw Report of the American College of Cardiology/American Heart Association Task Force on** 512 Report of the American College of Cardiology/American Heart Association Task Force on
513 Clinical Practice Guidelines. Hypertension. 2018;71:e13–e115. Clinical Practice Guidelines. Hypertension. 2018;71:e13-e115.
- 514 15. Echouffo-Tcheugui JB, Niiranen TJ, McCabe EL, Henglin M, Jain M, Vasan RS, Larson MG, 515 Cheng S. An Early-Onset Subgroup of Type 2 Diabetes: A Multigenerational, Prospective
516 Analysis in the Framingham Heart Study. Diabetes Care. 2020;43:3086–3093. Analysis in the Framingham Heart Study. Diabetes Care. 2020;43:3086-3093.
- 517 16. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss 518 18. The M, Savage PJ, Smith SC, et al. Diagnosis and management of the metabolic syndrome: an
19. The American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. 519 American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.
520 *Circulation*. 2005;112:2735–2752. Circulation. 2005; 112: 2735-2752.
- 521 17. Shortreed SM, Peeters A, Forbes AB. Estimating the effect of long-term physical activity on 522 **17. Shortreed SM, Peters A, Peters A, Forbes A, Formating the effect of long-term physical activity on**
522 **17. Shortreed SM, Peters A, Forbes A** R Particle of the effect of long-term physical activity on the Framing 522 cardiovascular disease and mortality: evidence from the Framingham Heart Study. Heart.
- 523 2013;99:649–654.
524 18. Schur EA, Melhorn SJ, Oh S-K, Lacy JM, Berkseth KE, Guyenet SJ, Sonnen JA, Tyagi V, 525 18. Rosalynn M, De Leon B, et al. Radiologic evidence that hypothalamic gliosis is associated
526 18. with obesity and insulin resistance in humans. Obesity (Silver Spring). 2015;23:2142–214 with obesity and insulin resistance in humans. Obesity (Silver Spring). 2015;23:2142-2148.
- 527 19. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti 528 57. S. Faiella-Tommasino J. Forman DE, et al. 2018
529 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS
- 529 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the
530 Management of Blood Cholesterol: A Report of the American College of
- 530 Management of Blood Cholesterol: A Report of the American College of
531 Cardiology/American Heart Association Task Force on Clinical Practice G
- 531 Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J American Coll Cardiol. 2019;73:e285–e350.
- Coll Cardiol. 2019;73:e285-e350. 532 Coll Cardiol. 2019;73:e285–e350.

It is made available under a CC-BY 4.0 International license.

534 20. Gordon T, Castelli W, Mychamic Wey, Million T, Castelli Wingh ashelv, Aperto Castelli as a
534 20. Gordon Tannel Wa, David McCastelli Wa, David Wa, D. Med.
535 20. Januar 20. Januar 20. Januar 20. Januar 20. Januar 534 protective factor against coronary heart disease. The Framingham Study. Am J Med.

535 1977;62:707–714.
536 21. Kreutzer C, Peters S, Schulte DM, Fangmann D, Türk K, Wolff S, van Eimeren T, Ahrens M, 537 537 Beckmann J, Schafmayer C, et al. Hypothalamic Inflammation in Human Obesity Is
538 Mediated by Environmental and Genetic Factors. *Diabetes*. 2017;66:2407–2415. Mediated by Environmental and Genetic Factors. Diabetes. 2017;66:2407-2415.

- 539 Z2. Götz A, Lehti M, Donelan E, Striese C, Cucuruz S, Sachs S, Yi C-X, Woods SC, Wright SD, 539 239 239 23. Götz A, Lehti M, Donelan B, Striese C, Cucuruz S, Striese C, Wright SD,
540 Müller TD, et al. Circulating HDL levels control hypothalamic astrogliosis via apoA-I. J Li 540 Müher TD, et al. Circulating HDL levels control hypothalamic astrogliosis via apoA-I. J Lipid
541 Mes. 2018;59:1649–1659.
- 541 Res. 2018;59:1649–1659. 543 Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL
544 cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011:365:2255–2267. cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-2267.
- 545 24. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, 546 Tomson J, Wallendszus K, Craig M, Jiang L, et al. Effects of extended-release niacin with
547 **Interpret Aung T, Aung T** laropiprant in high-risk patients. N Engl J Med. $2014;371:203-212$.
- 548 25. Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger 549 C, Menon V, Montalescot G, et al. Evacetrapib and Cardiovascular Outcomes in High-Risk
550 Vascular Disease. N Engl J Med. 2017;376:1933–1942. Vascular Disease. N Engl J Med. 2017;376:1933-1942.
- 551 26. Stocker SD, Ferreira CB, Souza GMPR, Abbott SBG. Brain Pathways in Blood Pressure 552 Regulation. Hypertension. 2024;81:383-386.
- 553 27. Rahmouni K. Cardiovascular Regulation by the Arcuate Nucleus of the Hypothalamus. 554 Hypertension. 2016:67:1064-1071.
- 555 28. Dampney RA, Michelini LC, Li D-P, Pan H-L. Regulation of sympathetic vasomotor activity 556 by the hypothalamic paraventricular nucleus in normotensive and hypertensive states. Am
557 JPhysiol Heart Circ Physiol. 2018;315:H1200–H1214. J Physiol Heart Circ Physiol. 2018;315:H1200-H1214.
- 558 29. Shi Z, Wong J, Brooks VL. Obesity: sex and sympathetics. Biol Sex Differ. 2020;11:10.
- 559 30. da Silva AA, Kuo JJ, Hall JE. Role of Hypothalamic Melanocortin 3/4-Receptors in Mediating 560 Chronic Cardiovascular, Renal, and Metabolic Actions of Leptin. Hypertension.
561 2004;43:1312–1317. 560 Chronic Cardiovascular, Renal, and Metabolic Actions of Leptin. Hypertension.
- 562 31. Shi Z, Li B, Brooks VL. Role of the Paraventricular Nucleus of the Hypothalamus in the 563 Sympathoexcitatory Effects of Leptin. Hypertension. 2015;66:1034-1041.
- 564 32. Cassaglia PA, Shi Z, Li B, Reis WL, Clute-Reinig NM, Stern JE, Brooks VL. Neuropeptide Y 565 acts in the paraventricular nucleus to suppress sympathetic nerve activity and its
566 haroreflex regulation. J Physiol. 2014;592:1655–1675. 565 acts in the paraventricular nucleus to suppress sympathetic nerve activity and its
566 baroreflex regulation. J Physiol. 2014;592:1655–1675. 566 baroreflex regulation. *J Physiol.* 2014;592:1655–1675.

It is made available under a CC-BY 4.0 International license.

- 567 33. Shi Z, Madden CJ, Brooks VL. Arcuate neuropeptide Y inhibits sympathetic nerve activity
568 via multiple neuropathways. *J Clin Invest*. 2017;127:2868–2880.
- 569 34. Douglass JD, Dorfman MD, Thaler JP. Glia: silent partners in energy homeostasis and 570 obesity pathogenesis. Diabetologia. 2017;60:226-236.
- 571 35. Valdearcos M, Robblee MM, Benjamin DI, Nomura DK, Xu AW, Koliwad SK. Microglia 572 dictate the impact of saturated fat consumption on hypothalamic inflammation and
573 heuronal function. *Cell Rep.* 2014:9:2124–2138. neuronal function. Cell Rep. 2014;9:2124-2138.
- 574 36. Purnell JQ, Braffett BH, Zinman B, Gubitosi-Klug RA, Sivitz W, Bantle JP, Ziegler G, Cleary 575 575 PA, Brunzell JD. Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1
576 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of 576 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of 577 Diabetes Care. 577 Diabetes Interventions and Complications (DCCT/EDIC) Study. *Diabetes Care*.
578 2017;40:1756–1762. 577 Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes Care.
- 579 37. Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-Weight 580 Fluctuations and Outcomes in Coronary Disease. N Engl J Med. 2017;376:1332-1340.
- 581 38. Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, 582 Crow RS, Curtis JM, Egan CM, et al. Cardiovascular effects of intensive lifestyle
583 intervention in type 2 diabetes. N Engl J Med. 2013;369:145–154. intervention in type 2 diabetes. N Engl J Med. $2013;369:145-154$.
- 584 39. Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 Receptor Agonists for the 585 35. Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes.
586 6 Girculation. 2022;146:1882–1894. Circulation. 2022;146:1882-1894.
- 587 40. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-588 10. Lindberg S, Hovingh GK, Kahn SE, Kushner RF, et al. Semaglutide and Cardiovascular
589 11. Outcomes in Obesity without Diabetes. N Enal J Med. 2023:389:2221–2232. Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221-2232.
- 590 d1. van Veldhuisen SL, Gorter TM, van Woerden G, de Boer RA, Rienstra M, Hazebroek EJ, van 591 Veldhuisen DJ. Bariatric surgery and cardiovascular disease: a systematic review and meta-
592 **Antia March A, Ann A, Ann A, Ann A, A, A, A, A, A, A, B, Van A, B, Van A, A**, 2022;43:1955–1969. analysis. Eur Heart J. 2022;43:1955-1969.
- 593 42. Liao T, Zhang S-L, Yuan X, Mo W-Q, Wei F, Zhao S-N, Yang W, Liu H, Rong X. Liraglutide 594 Lowers Body Weight Set Point in DIO Rats and its Relationship with Hypothalamic
595 Microglia Activation. *Obesity (Silver Spring)*. 2020;28:122–131. Microglia Activation. Obesity (Silver Spring). 2020;28:122-131.
- 596 da 43. Dané A, Videla L, Calvet À, Viaplana J, Vaqué-Alcázar L, Ibarzabal A, Rozalem-Aranha M, 597 Pegueroles J, Moize V, Vidal J, et al. Hypothalamic Inflammation Improves Through
198 Bariatric Surgery, and Hypothalamic Volume Predicts Short-Term Weight Loss Resp 598 Bariatric Surgery, and Hypothalamic Volume Predicts Short-Term Weight Loss Response in
599 Adults With or Without Type 2 Diabetes. *Diabetes Care*. 2024;dc232213. Adults With or Without Type 2 Diabetes. Diabetes Care. 2024;dc232213.
- 600 44. Prentice RL, Vasan S, Tinker LF, Neuhouser ML, Navarro SL, Raftery D, Gowda GN, 601 Pettinger M, Aragaki AK, Lampe JW, et al. Metabolomics Biomarkers for Fatty Acid Intake end and aranger M, aragami M, Lampe JW, Et al. Metabolomics Biomarkers for Fatty Acid Intake

It is made available under a CC-BY 4.0 International license.

-
- Frame Biomarker-Calibrated Fatty Acid Associations with Chronic Disease Risk in 1986.
603 Postmenopausal Women. J Nutr. 2023;153:2663–2677. 603 Postmenopausal Women. J Nutr. 2023;153:2663–2677.

604

It is made available under a CC-BY 4.0 International license.

605 Figure Legends

606 Figure 1. Axial brain T2-weighted image with anatomic locations of MBH and reference regions
607 of interest. Representative MRI images and regions of interest (ROIs). **A)** The amygdala was
608 identified at the level 608 identified at the level of the optic chiasm (oc) which was, on average, one slice inferior to the 609 inte
609 hypothalamus. B) Inset identified in A with representative bilateral placement of ROIs in the 609 hypothalamus. **B**) Inset identified in A with representative bilateral placement of ROIs in the othe optic in the slice with distinct be amygdala. C) The mediobasal hypothalamus (MBH) was identified on the slice with d 610 amygdala. C) The mediobasal hypothalamus (MBH) was identified on the slice with distinct
611 optic tracts (ot) and visible mammillary bodies (mb) and is at the level of the superior collici 611 optic tracts (ot) and visible mammillary bodies (mb) and is at the level of the superior colliculus 612 of the midbrain (superior to A). D) Inset identified in C with representative placement of 612 of the midbrain (superior to A). **D)** Inset identified in C with representative placement of 613 bilateral ROIs in the anterior hypothalamus, encompassing the location of the arcuate nu 613 bilateral ROIs in the anterior hypothalamus, encompassing the location of the arcuate nucleus,
614 adjacent to the 3rd ventricle. **E)** The putamen was identified at a level of the frontal horn of the 614 adjacent to the 3rd ventricle. **E)** The putamen was identified at a level of the frontal horn of the 615
615 alateral ventricles (with visible caudate head, internal capsule and globus pallidus). F) Inset 615 lateral ventricles (with visible caudate head, internal capsule and globus pallidus). F) Inset 614 set fo
616 lidentified in E with representative placement of bilateral ROIs in the putamen. oc, optic ch 616 identified in E with representative placement of bilateral ROIs in the putamen. oc, optic chiasm;
617 MBH, mediobasal hypothalamus; ot, optic tract; 3V, 3rd ventricle; mb, mammillary body; fhLV, 617 MBH, mediobasal hypothalamus; ot, optic tract; 3V, 3rd ventricle; mb, mammillary body; fhLV,
618 frontal horn of the lateral ventricle; ca, caudate; it, internal capsule; gp, globus pallidus. 618 frontal horn of the lateral ventricle; ca, caudate; it, internal capsule; gp, globus pallidus.
619

Figure 2. Sex- and age-adjusted associations of CVD risk factors with radiologic evidence of 620

621 hypothalamic gliosis by MBH/AMY T2 signal ratios. Scatterplots with linear fit lines of adjusted
622 associations between MBH/AMY T2 signal ratio and body mass index (BMI, A), HDL cholesterol

622 associations between MBH/AMY T2 signal ratio and body mass index (BMI, A), HDL cholesterol
623 (HDL-C, B), LDL cholesterol (LDL-C, C), and natural logarithm transformed fasting triglycerides

623 (HDL-C, B), LDL cholesterol (LDL-C, C), and natural logarithm transformed fasting triglycerides
624 (D). X-axis values represent MBH/AMY T2 signal ratios back-transformed from their natural

623 (HDL-C, B), LDL cholesterol (LDL-C, C), and natural logarithm transformed fasting triglycerides

625 logarithm value in the distribution derived from the linear fit performed on the natural
626 logarithm transformed predictor variable. P-values correspond to the two-sided probal

626 logarithm transformed predictor variable. P-values correspond to the two-sided probability of 627 the estimated t-statistic for the coefficient of the predictor in Model 1. MBH, mediobasal

627 the estimated t-statistic for the coefficient of the predictor in Model 1. MBH, mediobasal
628 hypothalamus: AMY, amygdala.

- 628 hypothalamus; AMY, amygdala.
629
-

Figure 3. Forest plot of odds ratios & 95% confidence intervals for T2 signal ratios and binary 630 631 outcomes related to cardiovascular risk and coronary heart disease. Results are from multiple
632 – logistic regression models. MRI-assessed T2 signal ratios were natural logarithm transformed 632 logistic regression models. MRI-assessed T2 signal ratios were natural logarithm transformed
633 and used as model predictors: MBH/AMY (primary), MBH/PUT (positive control), and PUT/AN 633 and used as model predictors: MBH/AMY (primary), MBH/PUT (positive control), and PUT/AMY
634 (negative control). Black squares represent the point estimates of the ORs for each model's 634 (negative control). Black squares represent the point estimates of the ORs for each model's 635
635 predictor, and solid lines represent 95% CIs for the ORs. ORs and 95% CIs are presented as t 635 predictor, and solid lines represent 95% CIs for the ORs. ORs and 95% CIs are presented as the 636
636 Change in odds for the outcome per a 1 SD difference in natural logarithm-transformed T2 636 betwer change in odds for the outcome per a 1 SD difference in natural logarithm-transformed T2
637 bignal ratio. Arrows indicate that the width of the 95% CI lies outside of the figure axis. The 637 signal ratio. Arrows indicate that the width of the 95% CI lies outside of the figure axis. The
638 dashed vertical line signifies the null OR of 1. BMI, body mass index; HDL-C, high-density 638 dashed vertical line signifies the null OR of 1. BMI, body mass index; HDL-C, high-density
639 lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; In(Triglycerides), natu 639 dipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ln(Triglycerides), natural
640 degarithm transformed fasting triglycerides: MBH, mediobasal hypothalamus: AMY, amygda 640 logarithm transformed fasting triglycerides; MBH, mediobasal hypothalamus; AMY, amygdala;
641 PUT, putamen. * Model 1 adjusted for age and sex. † Model 2 adjusted for model 1 covariates 641 PUT, putamen. * Model 1 adjusted for age and sex. † Model 2 adjusted for model 1 covariates
642 plus smoking. ‡ Model 3 adjusted for model 2 covariates plus diabetes treatment for BMI 642 plus smoking. ‡ Model 3 adjusted for model 2 covariates plus diabetes treatment for BMI
643 model or lipid treatment for HDL-C, LDL-C, and natural log-transformed triglycerides mode 643 model or lipid treatment for HDL-C, LDL-C, and natural log-transformed triglycerides models. §
644 Fully adjusted model includes model 3 covariates plus BMI, when appropriate. Fully adjusted model includes model 3 covariates plus BMI, when appropriate. 644 Fully adjusted model includes model 3 covariates plus BMI, when appropriate.

It is made available under a CC-BY 4.0 International license.

645 Table 1. Study population characteristics.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

646
647

 $*$ n=1 individual missing information about smoking status; $tn=3$ individuals missing information

648 about physical activity; \ddagger n=2 individuals missing information on triglycerides, HDL cholesterol, 649 blood glucose levels, and diabetes mellitus status; $\ddot{\textbf{s}}$ n=12 individuals missing information on

649 blood glucose levels, and diabetes mellitus status; § n=12 individuals missing information on 650 UDL cholesterol; $\vert \vert$ n=3 individuals excluded with fasting triglyceride concentrations greater

650 LDL cholesterol; $|\cdot|$ n=3 individuals excluded with fasting triglyceride concentrations greater
651 than 500 mg/dL; # n=20 individuals missing fasting triglyceride concentrations; **n=1 indivic

651 than 500 mg/dL; # n=20 individuals missing fasting triglyceride concentrations; **n=1 individual 652 missing information on DBP: *** n=1 individual series information on bBP: *** n=1 individual

652 missing information on DBP; *** n=1 individual missing information on hypertension
653 treatment: **** n=14 individuals missing MBH/PUT & PUT/AMY T2 signal ratios.

treatment; **** n=14 individuals missing MBH/PUT & PUT/AMY T2 signal ratios. $\mathbf{S} = \mathbf{S} \mathbf{S} \mathbf{S} + \mathbf{S} \mathbf{S} \mathbf{S} \mathbf{S} \mathbf{S} + \mathbf{S} \mathbf{S} \mathbf{S} \mathbf{S} \mathbf{S} \mathbf{S} + \mathbf{S} \mathbf{S} \mathbf{S} \mathbf{S} \mathbf{S} \mathbf{S} \mathbf{S} \mathbf{S} \mathbf$

654 Table 2. Associations of quantitative MRI measures and continuous outcomes related to cardiovascular risk.

655

656 Results are from multiple linear regression models. MRI-assessed T2 signal ratios were natural logarithm transformed and used as

657 model predictors: MBH/AMY (primary), MBH/PUT (positive control), and PUT/AMY (negative control). Coefficient and confidence

658 intervals represent the estimated change in outcome per 1 unit difference in the log-transformed T2 signal ratio. 659

660 BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ln(Triglycerides),

661 natural logarithm transformed fasting triglycerides; MBH, mediobasal hypothalamus; AMY, amygdala; PUT, putamen.

662

663 * Model 1 adjusted for age and sex.

664 † Model 2 adjusted for model 1 covariates plus smoking.

665 ‡ Model 3 adjusted for model 2 covariates plus diabetes treatment for BMI model or lipid treatment for HDL-C, LDL-C, and natural

666 log-transformed triglycerides models.

667 § Fully adjusted model includes model 3 covariates plus BMI, when appropriate.

International license

668 Figure 1. Axial brain T2-weighted image with anatomic locations of MBH and reference regions of interest.

670

671 Representative MRI images and regions of interest (ROIs). A) The amygdala was identified at 672
672 the level of the optic chiasm (oc) which was, on average, one slice inferior to the hypothalamus.

673 **b**) Inset identified in A with representative bilateral placement of ROIs in the amygdala. C) The

674 mediobasal hypothalamus (MBH) was identified on the slice with distinct optic tracts (ot) and

675 visible mammillary bodies (mb) and is at the level of the superior colliculus of the midbrain

676 (superior to A). **D**) Inset identified in C with representative placement of bilateral ROIs in the

- $\frac{1}{676}$ anterior to A). D) inset identified in C with representative placement of bilateral ROIs in the $2^{\frac{1}{12}}$
- b77 anterior hypothalamus, encompassing the location of the arcuate nucleus, adjacent to the 3rd
678 ventriele, **E**l The nutamen was identified at a level of the frontal bern of the lateral ventricles.
- 678 ventricle. **E)** The putamen was identified at a level of the frontal horn of the lateral ventricles 679 (with visible caudate head, internal capsule and globus pallidus). F) Inset identified in E with
- 679 (with visible caudate head, internal capsule and globus pallidus). FJ inset identified in E with
680 concessoriative placement of bilateral POIs in the putamen 660 representative placement of bilateral ROIs in the putamen.
co1
- 681
682
- oc, optic chiasm; MBH, mediobasal hypothalamus; ot, optic tract; 3V, 3rd 682 ventricle; mb,
- 683 mammillary body; fhLV, frontal horn of the lateral ventricle; ca, caudate; it, internal capsule; gp,
- 684 globus pallidus.

685 Figure 2. Sex- and age-adjusted associations of CVD risk factors with radiologic

687

688 Scatterplots with linear fit lines of adjusted associations between MBH/AMY T2 signal ratio and
689 body mass index (BMI, A), HDL cholesterol (HDL-C, B), LDL cholesterol (LDL-C, C), and natural 690 bogarithm transformed fasting triglycerides (D). X-axis values represent MBH/AMY T2 signal 691 ratios back-transformed from their natural logarithm value in the distribution derived from the 692 linear fit performed on the natural logarithm transformed predictor variable. P-values $\frac{652}{602}$ linear in performed on the natural logarithm transformed predictor variable. P-values 693 correspond to the two-sided probability of the estimated t-statistic for the coefficient of the 694 predictor in Model 1.

695 696 MBH, mediobasal hypothalamus; AMY, amygdala

Figure 3. Forest plot of odds ratios & 95% confidence intervals for T2 signal ratios and binary outcomes related to cardiovascular risk and coronary heart disease.

Results are from multiple logistic regression models. MRI-assessed T2 signal ratios were natural logarithm transformed and used as model predictors: MBH/AMY (primary), MBH/PUT (positive control), and PUT/AMY (negative control). Black squares represent the point estimates of the ORs for each model's predictor, and solid lines represent 95% CIs for the ORs. ORs and 95% CIs are presented as the change in odds for the outcome per a 1 SD difference in natural logarithm-transformed T2 signal ratio. Arrows indicate that the width of the 95% CI lies outside of the figure axis. The dashed vertical line signifies the null OR of 1.

MBH, mediobasal hypothalamus; AMY, amygdala; PUT, putamen; OR, odds ratio, CI, confidence interval.

- * Model 1 adjusted for age and sex.
- † Model 2 adjusted for model 1 covariates plus smoking.

‡ Model 3 adjusted for model 2 covariates plus lipid treatment for hypertension and coronary heart disease models, presence of hypertensi ion for diabetes mellitus models, or physical activity for metabolic syndrome models.

§ Fully adjusted model includes model 3 covariates plus BMI, when appropriate.

. [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) It is made available under a